Xentuzumab
Based on 1 publication(s) in Google Scholar
Xentuzumab (Anti-Human IGF1 and IGF2 Recombinant Antibody; BI836845) is a recombinant a human monoclonal antibody that targets IGF ligands IGF1 and IGF2. Xentuzumab inhibits both of IGF1 and IGF2 growth-promoting signalling and suppresses AKT activation.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit: 99.71%
- CAS. Nr.: 1417158-65-6
- Molecular Weight:143.7 kDa
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Xentuzumab
More
Biologische Aktivität
Human IgG1 lambda2
Human
IGF-1 & IGF-2
Xentuzumab (0.01-1 mM; 96 h) inhibits IGF type 1 receptor signaling and (0.1 μM; 48 h) AKT serine/threonine kinase (AKT) phosphorylation in VCaP, DuCaP, and MDA PCa 2b cell in a dose-dependent manner[1].
Xentuzumab (0.01-1 mM; 5-10 d) losses of antiproliferative activity against PTEN-null LNCaP or PC-3 cells when PTEN knockdown[1].
Xentuzumab (1 μM; 24-72 h) arrests cell cycle at sub-G1 phase and induces apoptosis in VCaP cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Prostate cancer VCaP cells
-
Concentration:0.1 μM
-
Incubation Time:24 h and 48 h
-
Result:Increased in cleaved caspase 3/7 and PARP.
Decreased the level of phosphorylation of FoxO3a (S253)/FoxO1 (T24).
-
Cell Line:Prostate cancer VCaP cells
-
Concentration:1 μM
-
Incubation Time:24 h, 48 h, and 72 h
-
Result:Increased in cleaved caspase 3/7 and induces cell apoptosis.
Increased the sub-G1 cell population.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Fox Chase CB17 severe combined immunodeficiency (SCID; CB17/lcr-Prkdc scid/lcrlcoCrl) male mice with LuCaP 96CR cell (s.c.)[1]
-
Dosage:200 mg/kg
-
Administration:Intraperitoneal injection; once weekly for 10 weeks; sacrificed 6 hours after the last dose
-
Result:Resulted in significant reductions in tumor volume.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG1 lambda2
ELISA, FACS, Functional assay
-
Immobilized Human IGF-I Protein, His Tag can bind Xentuzumab. The EC50 for this effect is 9.81 ng/mL.
Chemical Information
-
CAS. Nr. 1417158-65-6
-
Appearance Liquid
-
Molecular Weight 143.7 kDa
-
Color Colorless to light yellow
-
SMILES
[Xentuzumab]
-
Synonyms
BI 836845; Anti-Human IGF1 and IGF2 Recombinant Antibody
-
Versand
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Cancer Cell
Integrative molecular and spatial analysis reveals evolutionary dynamics and tumor-immune interplay of in situ and invasive acral melanoma. [Abstract]2024 Jun 10;42(6):1067-1085.e11. PMID: 38759655
Reinheit & Dokumentation
-
Data Sheet (262 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Verweise
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Xentuzumab Related Classifications
HY-P99274 Related Classifications
Powered by Bioz